Liisa Hurme has been appointed President and CEO of Orion Corporation as of November 1, 2022
News and research before you hear about it on CNBC and others. Redeem your 1 week free trial at StreetInsider Premium here.
ORION CORPORATION
STOCK EXCHANGE RELEASE – INSIDE INFORMATION
4/20/2022 at 8:30 AM EEST
Liisa Hurme appointed Pressdand Orion Corporation’s President and CEO since 1st of November 2022
Orion Corporation’s Board of Directors has appointed Liisa Hurme (b. 1967) as President and CEO of Orion Corporation and Chairman of the Orion Group’s Management Team as of November 1, 2022, until which his predecessor Timo Lappalainen maintain its position.
Liisa Hurme is PhD. in biochemistry. Hurme has worked for Orion for a long time in several management positions since 1999 and has been a member of the Management Team since 2008. He is currently the Head of Global Operations and the Chairman of the Board of the subsidiary Fermion Oy. Orionist. Hurme led the Originates business in 2008-2014 and Specialty Products in 2014-2018.
On September 17, 2021, Orion Corporation announced a succession plan for Orion’s President and CEO when Timo Lappalainen announced his intention to retire at the age of 60. Lappas will turn 60 in October 2022.
“We started the process of recruiting a new international CEO immediately after Lappalainen’s announcement last fall, and we have carefully evaluated both external and internal candidates for the position. Liisa Hurme is an excellent choice for Orion’s CEO. He combines Orion’s strong business expertise with the ability to promote Orion’s strategic development and has a solution-oriented and humane management style. In addition, thanks to her previous international designations in the pharmaceutical industry and life sciences, as well as her education background in science, Liisa has an in-depth understanding of the research and development environment that is important for the pharmaceutical industry, ”says Orion’s Chairman of the Board. members of the Board Mikael Silvennoinen.
“I would also like to thank Timo Lappalainen for his long and successful work as Orion’s CEO. During this time, the company has established itself as an international high-tech pharmaceutical company. At the same time, Orion has managed to maintain strong market leadership in Finland. I appreciate his performance-oriented and innovation-oriented attitude, which has also brought success to Orion’s shareholders, Silvennoinen says.
Liisa Hurme is very motivated for the task ahead. “I am excited about the opportunity to steer Orion’s growth and thank the Board for their trust in me. I believe that in my new role I will be able to utilize my expertise, my global networks and the extensive experience I have gained in various positions at Orion. Together with our dedicated and professional Orion staff, I do my best to stay on the path that Orion has been successful for over 100 years, ”says Hurme.
Timo Lappalainen, President and CEO of Orion Corporation, will resign as a member and chairmanf The Orion Group’s Management Team took office on November 1, 2022, when the new President and CEO took office. Lappalainen will continue to be employed by the Board as an advisor until the end of March 2023, after which he will retire.
“My time at Orion has been especially awesome thanks to the wonderful Orion staff I have been able to work with. It has also been rewarding to see innovations in our research and development, the latest of which – darolutamide – improves the quality of life of many prostate cancer patients. Our mission to build well-being has motivated me in a number of roles during my years at Orion. I am convinced that thanks to Liisa Hurme’s extensive expertise and experience, she has excellent opportunities to succeed as colleagues in the growth strategy work we have developed together. I wish Liisa all the best for her future role, ”says Timo Lappalainen.
Invitation press conference
Orion organizes a Finnish a press conference on the appointment of a new CEO for media representatives today is wednesday, April 20 from 11:45.m. towards 12:at 30 EEST.
The event will be held at Sanomatalo Venue Eliel, Töölönlahdenkatu 2Helsinki (entrance to Flik’s premises from the side of Elielinaukio). It is also possible participate in the event virtually through this link. In addition, media representatives are requested to provide their contact details (participant’s name, e-mail address and media name) in advance at [email protected].
Mikael Silvennoinen, Chairman of the Board of Orion, Liisa Hurme and Timo Lappalainen will be present at the event. Due to the quiet time, Orion does not comment on anything other than the appointment of a new CEO.
Liisa Hurmen’s CV and photo are attached to this release.
Orion Corporation
Mikael Silvennoinen
Chairman of the Board |
Olli Huotari
SVP, business operations |
Contact person:
Chairman of the Board Mikael Silvennoinen
tel. +358 50 1537
Contact person for the media and e.g.see requests:
Terhi Ormio, Senior Vice President, Communications, Orion Corporation
tel +358 50 966 4646; [email protected]
Lease CVa Hurme
Liisa Hurme
Ph.D (biochemistry)
Born 1967
Director of Global Operations as of January 1, 2019 and Chairman of the Board of Fermion Oy as of January 1, 2014
Career at Orion
2019 – Director, Global Operations
2014- Chairman of the Board of Fermion Oy
2014-2018 Director, Specialty Products
2008-2013 Vice President, Originating Products
2005-2007 Vice President, Urology and Oncology
2004-2005 Director of Drug Development Projects for Hormonal and Urological Therapies
2002-2004 portfolio manager
Project Manager 2001-2002
1999-2001 Researcher and Project Manager, Hormone Therapies
Previous career
1995-1999 Senior Research Associate, Pharmacia & Upjohn, Diagnostics (Sweden) and ELIAS GmbH (Germany) and Institute Pasteur (France)
Former key positions of trust
Member of the Board: PharmaService Oy 2014-2016, Bioindustries FIB 2010-2016
Member of the Economic and Social Committee of the European Federation of Pharmaceutical Industries and Organizations (EFPIA) 2010-2015, Member of the National Health Service Committee, NESO, 2014-2015
Liisa Hurme completed her dissertation in biochemistry at the Faculty of Science of the University of Helsinki in 1996.
Publisher:
Orion Corporation
Communication
Orionintie 1A, 02200 Espoo
http://www.orion.fi
http://www.twitter.com/OrionCorpIR
Orion is a Finnish pharmaceutical company operating worldwide – a builder of well-being. Orion develops, manufactures and markets human and veterinary medicines and the active ingredients of medicines. The company is constantly developing new drugs and treatment methods. The core therapeutic areas of Orion’s pharmaceutical research are currently neurological diseases, oncologies and respiratory diseases for which Orion is developing inhaled lung drugs. Orion’s net sales in 2021 were EUR 1,041 million and the company employed approximately 3,350 people at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.